Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01938638 · ClinicalTrials.gov registry record · Phase 1
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT01938638 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 80 participants.
The verdict
NCT01938638, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study Part A is to determine the safety, tolerability and the pharmacokinetics of BAY1143572 in subjects with advanced malignancies, which are either refractory to or ineligible for treatment with standard agents. The purpose of this study Part B is: Determine the safety, tolerability, pharmacokinetics (PK) and maximum tolerated dose (MTDG-CSF) of BAY1143572 with concurrent administration of the granulocyte colony-stimulating factors (G-CSF) in an intermittent and continuous dosing schedule in subjects with advanced malignancies.
Interventions
- DRUG BAY1143572
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2013-09-26 |
| Est. Completion | 2016-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01938638
The ClinicalTrials.gov registry entry for NCT01938638 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY1143572 is the first listed.
NCT01938638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01938638 about?
NCT01938638 is a clinical study titled "Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer". The purpose of this study Part A is to determine the safety, tolerability and the pharmacokinetics of BAY1143572 in subjects with advanced malignancies, which are either refractory to or ineligible for treatment with standard agents. The purpose of this study Part B is: Determine the safety, toler...
What is the current status of trial NCT01938638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2013-09-26. Estimated completion is 2016-09-19.
What interventions are being tested in trial NCT01938638?
The interventions under investigation include: BAY1143572 (DRUG).
Who is sponsoring clinical trial NCT01938638?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.